Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Filippo PietrantonioFotios LoupakisGiovanni RandonAlessandra RaimondiMassimiliano SalatiDario TrapaniFilippo PaganiIlaria DepetrisGiulia MaddalenaFederica MoranoSalvatore CoralloMichele PrisciandaroFrancesca CortiVincenzo GuariniAlessandro BocconiAntonio MarraCarmen BelliAndrea SpallanzaniMatteo FassanSara LonardiGiuseppe CuriglianoGiovanni FucàMaria Di BartolomeoFilippo de BraudPublished in: The oncologist (2020)
In this retrospective cohort study of 27 pretreated patients with microsatellite instability (MSI)-high cancers and Eastern Cooperative Oncology Group performance status of 2 or 3 not related to comorbidities, PD-1/PD-L1-based therapy induced a RECIST response in 33% of patients, with a median duration of 16.9 months, and an improvement of performance status in 52% of patients. MSI-high status can be used in clinical practice as a tumor-agnostic predictive biomarker to select critically ill patients with end-stage cancers for salvage immunotherapy.